Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 52-Week High – Still a Buy?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF)’s share price hit a new 52-week high on Wednesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada upgraded Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. The firm has a 50 day moving average price of $52.25 and a two-hundred day moving average price of $51.91. The company has a market capitalization of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.